[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-heart-failure-with-reduced-ejection-fraction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-heart-failure-with-reduced-ejection-fraction":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,38,75,98],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":27,"startDateStruct":30,"completionDateStruct":32,"leadSponsor":34,"locationsCount":37},"100527528","an-observational-study-to-learn-more-about-the-use-of-vericiguat-in-korean-people-with-chronic-heart-failure-with-reduced-ejection-fraction-hfref-in-real-world-setting-100527528",false,"NCT06148935","An Observational Study to Learn More About the Use of Vericiguat in Korean People With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) in Real-world Setting","Post-marketing Surveillance Study for Verquvo (Vericiguat) in Korean Heart Failure Patients With Reduced Ejection Fraction","Inclusion Criteria:\n\n* Adult aged 19 years or older\n* Chronic HF (NYHA functional class II, III, or IV) Reduced left ventricular ejection fraction (\\\u003C 45%) within 12 months before enrollment\n* Worsening of heart failure (hospitalized within 6 months before enrollment or intravenous diuretic therapy without hospitalization within 3 months)\n* Participants who have been prescribed Verquvo (Vericiguat) as per locally approved label and didn't receive Verquvo (Vericiguat) therapy previously.\n* Written informed consent from subject or legal representative; assent from subject when appropriate\n\nExclusion Criteria:\n\n* Contraindication according to the local authorized label (including known hypersensitivity to the drug substance or any of its components, pregnancy)\n* Participants participating in an investigational program with interventions outside of routine clinical practice","ALL","19 Years",{"count":19,"type":20},1350,"ESTIMATED","OBSERVATIONAL","This is an observational study in which only data are collected from participants receiving their usual treatment. The study is done in people with chronic heart failure with reduced ejection fraction (HFrEF). HFrEF is a long-term condition in which the heart does not pump blood as well as it should. Blood and fluid may collect in the lungs, blood vessels, and tissues causing shortness of breath or tiredness. Over time, heart failure can lead to other serious medical conditions that may result in hospital stays and death.\n\nThe study treatment vericiguat works by increasing the activity of an enzyme called soluble guanylate cyclase (sGC). sGC helps to regulate the heart and blood circulation. Vericiguat has already been studied in previous clinical studies and is available for doctors to prescribe to people with heart failure. This study will collect important data from real-world setting in Korea. The participants of this study are people with HFrEF who will receive vericiguat as prescribed by their doctors according to the approved product information\n\nThe main purpose of this study is to learn more about how safe vericiguat is in the participants. To do this, researchers will collect data on all medical problems (also called adverse events) that the participants have during the study. Doctors keep track of all adverse events, even if they do not think they might be related to the study treatment.\n\nFurther, researchers will collect data on how well vericiguat works and treatment patterns in the participants. For this, the following information will be collected:\n\n* occurrence of death due to heart and circulatory events\n* hospital stays due to heart conditions (failure)\n* dose levels of vericiguat and duration of treatment\n\nThe data for this study will come from medical records and visits that take place in routine practice. Participants will be treated with vericiguat and observed up to 12 months or until death or they leave the study, whatever comes first.",[24],"Chronic Heart Failure With Reduced Ejection Fraction","RECRUITING","2026-06-12",{"date":28,"type":29},"2026-06-15","ACTUAL",{"date":31,"type":29},"2023-11-30",{"date":33,"type":20},"2027-10-31",{"name":35,"class":36},"Bayer","INDUSTRY",1,{"id":39,"slug":40,"hasResults":11,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":44,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":16,"minAge":46,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":49,"phases":50,"briefSummary":52,"conditions":53,"keywords":54,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":37},"100640896","effects-of-repletion-of-sodium-chloride-on-natriuresis-blood-pressure-and-neurohormonal-activity-in-patients-with-chronic-heart-failure-with-reduced-ejection-fraction-100640896","NCT07614295","Effects of Repletion of Sodium Chloride on Natriuresis, Blood Pressure, and Neurohormonal Activity in Patients With Chronic Heart Failure With Reduced Ejection Fraction","Impact of Sodium Chloride Supplementation for Natriuresis, Blood Pressure and Neurohormonal Activity in Chronic Heart Failure With Reduced Ejection Fraction and Low Serum Sodium Concentration - Double-blinded, Placebo-controlled, Prospective Trial","RESALT-CHF","Inclusion Criteria:\n\n1. Chronic heart failure NYHA I-III.\n2. LVEF ≤40% documented in the echocardiography.\n3. Stable Heart Failure symptoms:\n\n   * Stable symptoms (subjectively declared by the patient) over the past three months.\n   * No increase in peripheral edema or body weight (declared by the patient).\n   * Loop diuretic dose equivalent to 80 mg of furosemide or 20 mg of torasemide daily, with no changes in the past three months.\n4. Age over 18 and under 85 years.\n5. Male or female.\n6. Use of guideline-directed medical therapy (GDMT), with each drug group at maximum tolerated doses but no more than half of the maximum dose.\n7. Systolic blood pressure \\\u003C100 mmHg and\u002For diastolic blood pressure \\\u003C60 mmHg.\n8. Resting heart rate up to 80 bpm.\n9. Serum sodium concentration \\\u003C140 mmol\u002FL, regardless of the cause.\n\nExclusion Criteria:\n\n1. Hospitalization due to heart failure decompensation within the last three months.\n2. Primary hypertrophic or restrictive cardiomyopathy, constrictive pericarditis.\n3. Systemic disease known to be associated with cardiac muscle infiltration.\n4. Significant valvular disease (moderate or severe stenosis of any valve, moderate or severe aortic or pulmonary regurgitation, severe tricuspid or mitral regurgitation).\n5. Severe renal impairment (eGFR \\\u003C30 mL\u002Fmin\u002F1.73 m² based on the MDRD formula).\n6. Stroke or transient ischemic attack (TIA) within the last three months.\n7. Cardiac resynchronization therapy (CRT), ICD, ablation, or pacemaker implantation (or planned implantation) within the last three months.\n8. Severe lung disease or \"cor pulmonale\" or other causes of isolated right ventricular failure not associated with left ventricular dysfunction.\n9. Severe lung disease with respiratory failure requiring home oxygen therapy.\n10. Body weight \\\u003C40 kg or ≥150 kg.\n11. Life expectancy \\\u003C12 months according to the investigator's assessment\n12. Pregnancy or breastfeeding.\n13. Ongoing drug or alcohol abuse.\n14. Lactose intolerance.","18 Years",{"count":48,"type":20},30,"INTERVENTIONAL",[51],"NA","The study is a single-center, prospective, randomized, placebo-controlled, double-blind trial conducted at the Institute of Heart Diseases and the Department of Cardiology of Wroclaw Medical University Hospital. It aims to evaluate the effects of three-month oral sodium chloride supplementation (3 g\u002Fday, equivalent to 1.2 g of sodium) versus placebo (lactose) in patients with chronic heart failure with reduced ejection fraction (HFrEF) and low serum sodium, who have not reached the maximum recommended doses of guideline-directed medical therapy (GDMT).\n\nA total of 30 patients will be enrolled, with 15 randomized to the experimental group receiving sodium chloride and 15 to the control group receiving placebo. Patient selection will involve careful screening, including recent serum sodium measurements, to ensure all inclusion and exclusion criteria are met.\n\nParticipants will attend bi-weekly visits to assess clinical parameters (medical history, EVEREST heart failure symptoms score, blood pressure, body weight), biochemical markers (serum: morphology, urea, creatinine, sodium, chloride, potassium, NT-proBNP, aldosterone, renin; urine: urea, creatinine, sodium, chloride, potassium), and the safety of supplementation (body weight, serum sodium and chloride, exercise tolerance). Visits will also allow attempts to optimize GDMT doses where clinically feasible, based on objective criteria (e.g., systolic blood pressure \\>110 mmHg and\u002For diastolic blood pressure \\>60 mmHg).\n\nCapsules containing sodium chloride or placebo will be prepared according to pharmacy standards to ensure intestinal release and maintain blinding. The Primary Investigator will remain blinded to treatment allocation. Follow-up will include both in-person and telephone visits, monitoring clinical status and safety parameters throughout the study period.\n\nSample size was calculated based on previous studies in this field, to achieve a type I error probability of 0.05 and a power of 0.80. At the end of the three-month supplementation, participants will undergo a comprehensive final assessment. Study data will be analyzed statistically to determine the effects of sodium chloride supplementation on natriuresis, blood pressure, neurohormonal activity, and the potential for optimizing GDMT in HFrEF patients with low serum sodium.",[24],[55,56,57,58,59,60,61,62,63],"sodium supplementation","sodium chloride","HFrEF","chronic heart failure","neurohormonal activity","aldosterone","renin","blood pressure","natriuresis","NOT_YET_RECRUITING","2026-05-25",{"date":67,"type":29},"2026-05-29",{"date":69,"type":20},"2026-05",{"date":71,"type":20},"2028-07",{"name":73,"class":74},"Wroclaw Medical University","OTHER",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":16,"minAge":46,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":49,"phases":84,"briefSummary":85,"conditions":86,"keywords":87,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":37},"100616861","a-prospective-single-center-randomized-controlled-clinical-study-evaluating-the-efficacy-and-safety-of-hyperbaric-oxygen-therapy-as-an-adjunctive-treatment-for-chronic-heart-failure-100616861","NCT07311109","A Prospective, Single-center, Randomized Controlled Clinical Study Evaluating the Efficacy and Safety of Hyperbaric Oxygen Therapy as an Adjunctive Treatment for Chronic Heart Failure","Inclusion Criteria:\n\n1. Diagnostic Criteria\n\n   Diagnosis of chronic heart failure according to the Chinese Guidelines for the Diagnosis and Management of Heart Failure (2024), and meeting the following conditions:\n\n   1.1 Left Ventricular Ejection Fraction (LVEF) ≤ 40% (HFrEF group). 1.2 Presence of chronic HF symptoms (NYHA functional class II-IV) or objective evidence (e.g., elevated natriuretic peptides, structural cardiac abnormalities).\n\n   1.3 Disease duration ≥ 3 months, with no adjustments to the foundational anti-heart failure regimen within the past month.\n2. Age and Informed Consent 2.1 Aged 18 to 70 years (inclusive). 2.2 Understand the study purpose and provide signed informed consent.\n3. Treatment Stability 3.1 Received guideline-recommended, standardized \"New Four Pillars\" anti-heart failure therapy (ARNI\u002FACEI\u002FARB + β-blocker + MRA + SGLT2 inhibitor) for at least 2 weeks prior to enrollment, with no changes in the past month.\n\n3.2 No diuretic dose adjustments within the past 5 days and no clinical signs of fluid overload (e.g., weight gain of ≥ 2 kg\u002Fweek, new-onset pulmonary edema).\n\n\\-\n\nExclusion Criteria:\n\n* Absolute Contraindications\n\n  1. Untreated pneumothorax or pneumomediastinum.\n  2. Claustrophobia, agitation or inability to cooperate, or conditions unsuitable for HBOT such as angle-closure glaucoma or eustachian tube occlusion.\n  3. Unstable vital signs.\n  4. Concurrent intracranial hemorrhage, intracranial mass, malignant tumor, uncontrolled epilepsy, psychiatric disorder, coagulation dysfunction, or other severe uncontrolled comorbidities.\n  5. Severe pulmonary bullae or emphysema.\n  6. Active internal bleeding or coagulopathy.\n  7. Uncontrolled hyperpyrexia (body temperature \\>38.0°C).\n  8. Concurrent use of disulfiram, bleomycin, or cisplatin chemotherapy. Relative Contraindications\n  9. Uncontrolled hypertension (systolic BP \\>160 mmHg or diastolic BP \\>100 mmHg).\n  10. Severe cardiac arrhythmias (e.g., third-degree atrioventricular block without a pacemaker, frequent ventricular tachycardia).\n  11. Chronic obstructive pulmonary disease (FEV1 \\\u003C50% of predicted) or active asthma.\n  12. Psychiatric or cognitive impairment preventing cooperation with the therapy. Comorbidity Restrictions\n  13. End-stage renal disease (dialysis-dependent).\n  14. Terminal malignancy (life expectancy \\\u003C6 months).\n  15. Pregnancy or lactation (a negative pregnancy test is required for women of childbearing potential).\n\n      Recent Clinical Events\n  16. Acute myocardial infarction or unstable angina within the past 4 weeks.\n  17. Hospitalization or emergency department visit for acute heart failure within the past 2 weeks.\n  18. Current use of intravenous positive inotropic agents.\n  19. Within 6 months after cardiac surgery.\n  20. Use of any mechanical circulatory support.\n  21. Participants with a 6-minute walk test result exceeding 450 meters or who are unable to complete the test.\n\n      Other Exclusion Conditions\n  22. Inability to complete follow-up (e.g., planned relocation, non-compliance with follow-up assessments).\n  23. Concurrent participation in any other clinical trial that may interfere with the outcomes of this study.\n  24. Unforeseen circumstances judged by the investigators to be ineligible.","70 Years",{"count":83,"type":20},150,[51],"This study aims to investigate whether adjunctive hyperbaric oxygen therapy, compared to guideline-directed medical therapy with the \"New Four Pillars\" (ARNI\u002FACEI\u002FARB + β-blocker + MRA + SGLT2 inhibitor) alone, improves cardiac function in patients with chronic heart failure, and to evaluate its efficacy and safety.",[24],[58,88],"HBOT","2025-12-16",{"date":91,"type":29},"2025-12-30",{"date":93,"type":20},"2025-12-15",{"date":95,"type":20},"2028-12-31",{"name":97,"class":74},"Fujian Medical University",{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":16,"minAge":46,"maxAge":4,"enrollmentInfo":105,"targetDuration":4,"studyType":49,"phases":107,"briefSummary":109,"conditions":110,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":37},"100481812","phase-3-s086-tablets-for-chronic-heart-failure-with-reduced-ejection-fraction-100481812","NCT05553886","S086 Tablets for Chronic Heart Failure With Reduced Ejection Fraction","A Randomized, Double-blind, Positive-drug Parallel Controlled, Multicenter Phase III Trial of the Efficacy and Safety of S086 Tablets in Patients With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)","Inclusion Criteria:\n\n1. Patients with chronic heart failure (NYHA grade ⅱ-ⅳ) with reduced ejection fraction (LVEF≤40%) and elevated BNP were diagnosed 1a.\n2. Patients received a stable dose of the underlying treatment for heart failure, defined as no change in dose for at least 4 weeks before screening 1b.\n3. Volunteer to participate in the trial and sign an informed consent form 1c.\n\nExclusion Criteria:\n\n1. Previous continuous administration of sacubitril valsartan sodium 150mg bid or more for more than 3 months 1a.\n2. Use of other study drugs or use of any study medical device within 1 day of the visit or within 30 days prior to the visit or within 5 half-lives of the drug, whichever is longer 1b.\n3. Known or suspected allergy to S086, sacubitril valsartan sodium, ARB, ACEI, or enkephin inhibitor (NEPI), and known or suspected contraindications to sacubitril valsartan sodium 1c.\n4. A previous history of intolerance to the recommended target dose of ACEI or ARB 1d.\n5. He had a history of angioedema 1e.\n6. Acute coronary syndrome occurred within 6 weeks before visit 1 1f.",{"count":106,"type":20},5,[108],"PHASE3","A randomized, double-blind, positive-drug parallel controlled, multicenter phase III trial of the efficacy and safety of S086 tablets in patients with chronic heart failure with reduced ejection fraction (HFrEF)",[24],"2022-10-31",{"date":113,"type":29},"2022-11-03",{"date":115,"type":29},"2021-12-21",{"date":117,"type":20},"2026-12-31",{"name":119,"class":74},"Shenzhen People's Hospital"]